Marker Therapeutics Inc MRKR
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $1.58
- Day Range
- $1.51–1.59
- 52-Week Range
- $0.81–4.07
- Bid/Ask
- $1.30 / $1.55
- Shares Outstanding
- 16.67M
- Market Cap
- $25.18M
- Volume/Avg
- 70,902 / 73,927
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 5
Valuation
|
Metric
|
MRKR
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.03 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
MRKR
|
|---|---|
Quick Ratio | 4.48 |
Current Ratio | 4.79 |
Interest Coverage | — |
Quick Ratio
MRKR
Profitability
|
Metric
|
MRKR
|
|---|---|
Return on Assets (Normalized) | −58.67% |
Return on Equity (Normalized) | −71.39% |
Return on Invested Capital (Normalized) | −75.20% |
Return on Assets
MRKR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|SK%%zw | LOCK|ZL$Z | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|H$R^yJ | LOCK|x!@K> | $70B | |||
| argenx SE ADR
ARGX
| LOCK|Qv!YWM | LOCK|!% | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|dm!yg?d | LOCK|%v$$ | $40B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|K@yvJ$^ | LOCK|X#^ | $36B | |||
| Moderna Inc
MRNA
| LOCK|c>Tfsyv | LOCK|zD | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|&mh%%F!j | LOCK|@Bykc | $25B | |||
| Incyte Corp
INCY
| LOCK|Fg?c^F | LOCK|c&$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|GVPbNn | LOCK|W?! | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|F^Sh@> | LOCK|!& | $17B |
United States